Special Issue "Close links between Cold Shock Proteins and Cancer"
Deadline for manuscript submissions: 31 December 2020.
2. German Cancer Consortium (DKTK) Partnersite Tuebingen, German Cancer Research Center (DKFZ), Heidelberg, Germany
Interests: YB-1, solid tumors, radiotherapy, DNA damage response, therapy resistance
Interests: YB-1; cancer biomarkers; breast cancer; genomics
Cold shock proteins (CSPs) are the most evolutionarily-conserved nucleic acid binding proteins, and regulate a multitude of cellular functions, including proliferation, survival, and stress response. Many of these properties are considered hallmarks of cancer cells. Therefore, it is becoming increasingly acknowledged that these underrated molecules play an important role in cancer biology. DNA-binding protein-A (Dbp-A) and Y-box-binding protein-1 (YB-1; also known as Dbp-B) are the two most characterized CSPs, functioning by regulating the transcription and translation of key proteins, accelerating the repair of a wide variety of DNA damages and sorting miRNAs, to name just a few of their mechanisms of action described to date. We now know that CSPs are also secreted from cells via exosomes and the Golgi apparatus, and bind to cell surface receptors (e.g. Notch receptors) to activate intracellular signaling cascades. YB-1 also regulates the transcription of genes involved in drug resistance and malignant progression. Not surprisingly, high levels of YB-1 protein or YBX1 mRNA have been associated with poor prognosis of patients in a wide range of cancers. Thus, YB-1 has been proposed as both a biomarker and a potential therapeutic target for many cancer types.
We invite researchers in the field to contribute to this Special Issue, covering subjects that support the link between CSPs and cancer, including descriptions of the underlying signaling pathways involving CSPs or contributing to the activation of CSPs, in addition to strategies targeting CSPs or CSP-dependent signaling pathways to treat cancer and overcome therapy resistance. Furthermore, given that we live in the “omics” era, we also encourage contributions from bioinformatic analyses of large datasets to further understand the role of the CSPs in cancer.
Prof. Dr. Mahmoud Toulany
Dr. Annette Lasham
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- cold shock proteins
- Y-box-binding protein-1
- DNA-binding protein-A
- signaling pathways
- therapy resistance
- inflammatory disease
- targeted therapies